Jiangsu Nhwa Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of June 2026: 26.45%

Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has an Asset Resilience Ratio of 26.45% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002262 working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥2.52 Billion
≈ $369.05 Million USD Cash + Short-term Investments

Total Assets

CN¥9.54 Billion
≈ $1.40 Billion USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Jiangsu Nhwa Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 002262 asset base.

Liquid Assets Composition Over Time

This chart breaks down Jiangsu Nhwa Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Jiangsu Nhwa Pharmaceutical Co Ltd (002262) long-term investment share to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥2.52 Billion 26.45%
Total Liquid Assets CN¥2.52 Billion 26.45%

Asset Resilience Insights

  • Very High Liquidity: Jiangsu Nhwa Pharmaceutical Co Ltd maintains exceptional liquid asset reserves at 26.45% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Jiangsu Nhwa Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jiangsu Nhwa Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Kamada
TA:KMDA
Drug Manufacturers - Specialty & Generic 0.00%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Viatris Inc
NASDAQ:VTRS
Drug Manufacturers - Specialty & Generic 1.48%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 4.31%
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
Drug Manufacturers - Specialty & Generic 1.01%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Drug Manufacturers - Specialty & Generic 5.90%

Annual Asset Resilience Ratio for Jiangsu Nhwa Pharmaceutical Co Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Jiangsu Nhwa Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 27.85% CN¥2.57 Billion
≈ $375.93 Million
CN¥9.22 Billion
≈ $1.35 Billion
-0.26pp
2024-12-31 28.12% CN¥2.37 Billion
≈ $347.24 Million
CN¥8.44 Billion
≈ $1.24 Billion
+9.90pp
2023-12-31 18.22% CN¥1.33 Billion
≈ $195.35 Million
CN¥7.33 Billion
≈ $1.07 Billion
-4.19pp
2022-12-31 22.40% CN¥1.45 Billion
≈ $212.47 Million
CN¥6.48 Billion
≈ $948.40 Million
+3.83pp
2021-12-31 18.58% CN¥1.06 Billion
≈ $154.88 Million
CN¥5.70 Billion
≈ $833.68 Million
+1.18pp
2020-12-31 17.39% CN¥837.00 Million
≈ $122.48 Million
CN¥4.81 Billion
≈ $704.17 Million
+15.73pp
2019-12-31 1.67% CN¥70.00 Million
≈ $10.24 Million
CN¥4.20 Billion
≈ $614.81 Million
-1.68pp
2018-12-31 3.35% CN¥135.00 Million
≈ $19.75 Million
CN¥4.03 Billion
≈ $590.13 Million
-6.83pp
2017-12-31 10.18% CN¥336.05 Million
≈ $49.17 Million
CN¥3.30 Billion
≈ $483.12 Million
+6.14pp
2016-12-31 4.03% CN¥120.00 Million
≈ $17.56 Million
CN¥2.97 Billion
≈ $435.32 Million
--
pp = percentage points

About Jiangsu Nhwa Pharmaceutical Co Ltd

SHE:002262 China Drug Manufacturers - Specialty & Generic
Market Cap
$3.22 Billion
CN¥22.01 Billion CNY
Market Cap Rank
#4720 Global
#764 in China
Share Price
CN¥21.73
Change (1 day)
+0.56%
52-Week Range
CN¥18.23 - CN¥28.92
All Time High
CN¥31.19
About

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin… Read more